scholarly journals Disseminated Multidrug-Resistant Tuberculosis in a Young Patient: A Rare Case Report

2020 ◽  
Vol 8 (1) ◽  
pp. 26
Author(s):  
Ritu Dadra ◽  
NirmalChand Kajal ◽  
Balbir Malhotra ◽  
Prasanth Pandiyaraj ◽  
Lakhvir Kaur ◽  
...  
2020 ◽  
Vol 15 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Asha K. Rajan ◽  
Ananth Kashyap ◽  
Manik Chhabra ◽  
Muhammed Rashid

Rationale: Linezolid (LNZ) induced Cutaneous Adverse Drug Reactions (CADRs) have rare atypical presentation. Till date, there are very few published case reports on LNZ induced CADRs among the multidrug-resistant patients suffering from Infective Endocarditis (MDR IE). Here, we present a rare case report of LNZ induced CARs in a MDR IE patient. Case report: A 24-year-old female patient was admitted to the hospital with chief complaints of fever (101°C) associated with rigors, chills, and shortness of breath (grade IV) for the past 4 days. She was diagnosed with MDR IE, having a prior history of rheumatic heart disease. She was prescribed LNZ 600mg IV BD for MDR IE, against Staphylococcus coagulase-negative. The patient experienced flares of cutaneous reactions with multiple hyper-pigmented maculopapular lesions all over the body after one week of LNZ therapy. Upon causality assessment, she was found to be suffering from LNZ induced CADRs. LNZ dose was tapered gradually and discontinued. The patient was prescribed corticosteroids along with other supportive care. Her reactions completely subsided and infection got controlled following 1 month of therapy. Conclusion: Healthcare professionals should be vigilant for rare CADRs, while monitoring the patients on LNZ therapy especially in MDR patients as they are exposed to multiple drugs. Moreover, strengthened spontaneous reporting is required for better quantification.


2006 ◽  
Vol 27 (8) ◽  
pp. 642-644 ◽  
Author(s):  
Fernando Baquero-Artigao ◽  
Maria Jesús Garcia-Miguel ◽  
Rosa Merino ◽  
Julia García-Consuegra ◽  
Fernando del Castillo

2018 ◽  
Vol 3 (2) ◽  
pp. 492-494
Author(s):  
Yamuna Agrawal ◽  
Rajan Shah ◽  
Brikh Raj Joshi ◽  
Vivek Kattel

Juvenile polyposis syndrome prevalence is 1 in 16,000 to 1 in 100,000 which usually present at the age of 20 years. The tumor is likely to change into malignant condition in 20% of cases. Here we present this rare syndrome in a 16-year boy. BJHS 2018;3(2)6:492-494.


2017 ◽  
Vol 3 ◽  
pp. 199-204
Author(s):  
Bogusz J. Aksak-Wąs ◽  
Magdalena Leszczyszyn-Pynka ◽  
Miłosz Parczewski ◽  
Adam Krzyształowski

Sign in / Sign up

Export Citation Format

Share Document